Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 91 to 105 of 122 results for bacterial infections

  1. Complicated intra-abdominal infections: ceftolozane/tazobactam (ESNM75)

    Summary of the evidence on ceftolozane/tazobactam for treating complicated intra-abdominal infections to inform local NHS planning and decision-making

  2. Genedrive MT-RNR1 ID Kit for detecting a genetic variant to guide antibiotic use and prevent hearing loss in babies: early value assessment (HTE6)

    Early value assessment (EVA) guidance on the Genedrive MT-RNR1 ID Kit for detecting a genetic variant to guide antibiotic use and prevent hearing loss in babies...

  3. Prevena incision management system for closed surgical incisions (MIB173)

    NICE has developed a medtech innovation briefing (MIB) on Prevena incision management system for closed surgical incisions .

  4. Use of biomarkers to diagnose and initiate treatment:- What is the clinical and cost effectiveness of procalcitonin (PCT) point-of-care tests at initial triage for diagnosis of serious infection and the initiation of appropriate antibiotic therapy?

    procalcitonin (PCT) point-of-care tests at initial triage for diagnosis of serious infection and the initiation of appropriate...

  5. Abortion care (NG140)

    This guideline covers care for women of any age (including girls and young women under 18) who request an abortion. It aims to improve the organisation of services and make them easier for women to access. Detailed recommendations on conducting abortions at different gestational stages are also included, to ensure that women get the safest and most effective care possible.

  6. Antenatal care (NG201)

    This guideline covers the routine antenatal care that women and their babies should receive. It aims to ensure that pregnant women are offered regular check-ups, information and support. We have also published a guideline on postnatal care , which covers the topics of emotional attachment and baby feeding.

  7. Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis (TA988)

    Evidence-based recommendations on ivacaftor–tezacaftor–elexacaftor (Kaftrio) plus ivacaftor (Kalydeco), tezacaftor–ivacaftor (Symkevi) plus ivacaftor, and lumacaftor–ivacaftor (Orkambi) for treating cystic fibrosis.

  8. What is the optimal antibiotic prophylaxis regimen for women who are having a surgical abortion?

    for women who are having medical abortion showed lower rates of severe infection with antibiotic prophylaxis compared with no antibiotic...

  9. Oxyzyme and Iodozyme 2-layer hydrogel wound dressings with iodine for treating chronic wounds (MIB11)

    NICE has developed a Medtech Innovation Briefing (MIB) on Oxyzyme and Iodozyme 2-layer hydrogel wound dressings with iodine for treating chronic wounds

  10. What is the clinical effectiveness of topical treatments (antibiotics and antiseptics) compared with oral antibiotics for the treatment of infected leg ulcer?

    offered for adults with a leg ulcer when there are symptoms or signs of infection. They agreed that there was no difference in outcomes...

  11. Developmental follow-up of children and young people born preterm (NG72)

    This guideline covers the developmental follow-up of babies, children and young people under 18 years who were born preterm (before 37+0 weeks of pregnancy). It explains the risk of different developmental problems and disorders, and specifies what extra assessments and support children born preterm might need during their growth and development.

  12. QuickChange Incontinence Wrap for urinary incontinence in men (MIB237)

    NICE has developed a medtech innovation briefing (MIB) on QuickChange Incontinence Wrap for urinary incontinence in men .

  13. What overall osmolality (or concentration of calcium and glucose/dextrose) in parenteral nutrition can determine whether to administer centrally or peripherally?

    stopped working and needs to be removed, or there are concerns about line infection). The committee did not define how long parenteral...

  14. Committee B members

    Find out more about the NICE technology appraisal advisory committee B members and their registered interests

  15. Neonatal parenteral nutrition (NG154)

    This guideline covers parenteral nutrition (intravenous feeding) for babies born preterm, up to 28 days after their due birth date and babies born at term, up to 28 days after their birth. Parenteral nutrition is often needed by preterm babies, critically ill babies, and babies who need surgery.